Sparsentan bulk supplier for pharma manufacturers

Sparsentan 200mg, 400mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200mg, 400mg

Reference Brands: Filspari (USA)

Sparsentan is an oral dual endothelin type A receptor (ET_A) and angiotensin II type 1 receptor (AT_1) antagonist, designed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. It is marketed under the brand name Filspari and available in 200 mg and 400 mg tablets. Because of its novel mechanism and risk profile (including hepatotoxicity), it is subject to a restricted drug-distribution program.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Sparsentan? List it or send an offer →

Product Description:

Sparsentan blocks two receptors at once: the endothelin type A receptor and the angiotensin II type 1 receptor. Both pathways drive vasoconstriction, glomerular pressure, inflammation and fibrosis in the kidney, and both contribute to the protein leak that damages the nephron in IgA nephropathy. Blocking them in one molecule reduces proteinuria more than blocking the renin-angiotensin system alone.

It is used to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression. Approval came on the surrogate endpoint of proteinuria reduction, with confirmatory data on preserving kidney function following. Two risks define its use. Endothelin receptor antagonists as a class cause liver injury and are teratogenic, so liver enzymes are monitored, pregnancy is excluded before and during treatment, and in the US it is available only through a restricted programme. It also lowers blood pressure and can cause hyperkalaemia and fluid retention, so it is not combined with an ACE inhibitor or ARB.

Sourcing notes. Originator product, on patent, no generic. Authorised in the US and the EU; registration elsewhere is developing. Restricted distribution with prescriber and patient enrolment applies in several markets, so supply runs through authorised channels and specialist nephrology centres.

Sparsentan — third party manufacturing & bulk supply

Sparsentan 200mg, 400mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sparsentan is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sparsentan listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sparsentan →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Sparsentan is used to treat rare kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis (FSGS). It helps reduce proteinuria (excess protein in the urine) and slows the progression of kidney damage. Sparsentan works by blocking two key pathways involved in kidney injury — endothelin type A and angiotensin II type 1 receptors — offering dual protection to the kidneys.

Sparsentan is made from the active ingredient sparsentan, a dual-acting angiotensin II and endothelin receptor antagonist. Its chemical name is (2E)-3-[2-butyl-1-[(4′-carboxy[1,1′-biphenyl]-4-yl)methyl]-7-(2-methylpropyl)-2,6-dioxo-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-yl]-N-(2-hydroxy-2-phenylethyl)acrylamide. It is formulated with excipients such as lactose monohydrate, cellulose, and magnesium stearate depending on the dosage form.

The trade name of sparsentan is Filspári in the United States and Kinpeygo in the European Union.

Sparsentan (Filspári/Kinpeygo) is developed and marketed by Travere Therapeutics in the United States and by CSL Vifor in Europe under a licensing agreement.

The generic name of the drug is sparsentan.

The brand names of sparsentan are Filspári (USA) and Kinpeygo (EU).

Sparsentan is manufactured in the United States by Travere Therapeutics and in Europe by CSL Vifor, with global distribution to markets where treatment for IgA nephropathy and FSGS is approved.